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BACKGROUND: Capecitabine is known to rarely cause raised serum triglycerides (TG). In our centre, several patients receiving
capecitabine developed raised TG levels corresponding to the ‘very high risk’ category for potentially serious acute pancreatitis.
METHODS: A fasting blood lipid screening protocol was introduced into clinical practice for patients receiving capecitabine. Patients
with TGs 45mmoll
 1 were treated and followed up. An 18-month prospective audit was performed to establish the incidence and
severity of capecitabine-induced hypertriglyceridaemia (CIHT).
RESULTS: A total of 304 patients received capecitabine for colorectal cancer between January 2008 and June 2009. Of these, 212
patients (70%) were screened and 8 (3.7%) developed clinically significant hypertriglyceridaemia requiring lipid-lowering therapy. Two
of the eight patients had diabetes and one had pre-existing dyslipidaemia. One suffered cerebral infarction during chemotherapy.
There were no cases of acute pancreatitis. Follow-up showed that serum TGs safely and rapidly returned to normal with appropriate
treatment without discontinuation of capecitabine.
CONCLUSIONS: This is the first prospective study evaluating CIHT. These results suggest that it should be classed as a ‘common’
undesired effect of capecitabine. Despite this, the incidence does not justify routine screening in all patients. Targeted screening in
those with diabetes or pre-existing hyperlipidaemia is recommended, together with adoption of a clear management policy.
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A number of anti-cancer drugs, such as tamoxifen and rapamycin,
are known to cause abnormal lipid metabolism. Capecitabine is a
prodrug of the cytotoxic agent 5-fluorouracil (5-FU), and is
commonly used in the management of metastatic gastrointestinal
(GI) and breast malignancies and as adjuvant therapy for
colorectal carcinoma. It is associated with several adverse effects
including diarrhoea, plantar-palmar erythrodysaesthesia and
nausea.
Hypertriglyceridaemia has been associated with capecitabine
treatment. In the manufacturer’s product literature, National
Cancer Institute Common Toxicity Criteria (NCI CTC) grade 3
(45- to 10-fold increase) or 4 (410-fold increase above upper
limit of normal range (ULN)) hypertriglyceridaemia is listed as an
uncommon (X0.1 to o1%) toxicity (Roche Pharmaceuticals,
2009). However, in five of the first main published capecitabine
phase I studies in GI cancers (Budman et al, 1998; Cassidy et al,
1998; Mackean et al, 1998; Villalona-Calero et al, 1999; Pronk
et al, 2000) involving a total of 143 patients, significant hyper-
triglyceridaemia was never reported. As it is thought to be an
infrequent side effect and not currently tested for in routine
practice, it is not reported in large phase III studies either (Cassidy
et al, 2008).
Despite being listed as an uncommon toxicity, nine instances of
grade 3/4 non-fasting hypertriglyceridaemia, at levels corresponding
to the ‘high risk’ (410mmoll
 1) or ‘very high risk’ (420mmoll
 1)
categories for development of potentially life-threatening acute
pancreatitis, were noted anecdotally during 2007. All patients had
been receiving capecitabine (either as 1250mgm
 2 twice daily on
days 1–14 of 21-day cycle as monotherapy or 1000mgm
 2 in
combination regimens) for colorectal cancer at the Edinburgh
Cancer Centre.
In each of these cases, the hospital laboratory had initiated lipid
testing after observing that routine pre-chemotherapy blood
samples were frankly lipaemic. The highest chemotherapy-related
non-fasting triglyceride (TG) level noted was 56mmoll
 1,i na
patient with established diabetes (27 times the ULN).
To date, there have been five publications involving seven
detailed case reports of severe capecitabine-induced hypertrigly-
ceridaemia (CIHT) (Koutras et al, 2006; Kurt et al, 2006; Bar-Sela
and Haim, 2009; Garg et al, 2009; Orphanos et al, 2010), with up to
20-fold reported increases from pre-treatment levels, all requiring
interruption of capecitabine therapy. There have also been case
reports of capecitabine-induced pancreatitis (Jones and Valero,
2003; Yucel and van Warmerdam, 2010) and of the association
between CIHT and diabetes (Garg et al, 2009). The authors of the
Received 13 April 2010; revised 22 June 2010; accepted 22 June 2010;
published online 27 July 2010
*Correspondence: Dr CO Michie; E-mail: Caroline.Michie@luht.scot.nhs.uk
British Journal of Cancer (2010) 103, 617–621
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
slatter report state that patients receiving capecitabine therapy
should have regular monitoring of lipid and glucose levels. Both of
these tests are most meaningful when performed after an overnight
fast. Logistically, performing regular fasting blood screening on all
patients receiving such a commonly used cancer drug would
require significant additional resource and clinical co-ordination.
However, other than one small study in which 5 out of 12 patients
developed CIHT (Stathopoulos et al, 2007), published data does
not indicate whether the incidence and severity of this side effect
support routine lipid testing.
Therefore, before considering widespread incorporation of lipid
monitoring into clinical practice, the true frequency and severity of
this side effect in routine practice needs to be established.
The main concern of an acutely raised serum TG level is acute
pancreatitis. However, many patients are treated with capecitabine
over a 6-month period, on an adjuvant basis, and chronic high
levels could also have an impact on their general health and
atherosclerosis risk.
STUDY OBJECTIVES
The primary study objective was to prospectively audit the
incidence of severe CIHT when incorporating lipid testing into
routine clinical practice for a trial period. The secondary objectives
were to identify any specific high-risk groups that might be
suitable for targeted screening, if screening the whole population
was not felt to be justified or practical.
PATIENTS AND METHODS
A management protocol for the timing of blood sampling and the
management of hypertriglyceridaemia was formulated in colla-
boration with a local metabolic medicine specialist (MS; see
Table 1 for protocol). Ethical approval for the audit was obtained
from the Local Research Ethics Committee. All staff involved in the
care of lower GI cancer patients receiving capecitabine, including
general practitioners (GPs), were informed about the new lipid
testing protocol and briefed as to the purpose of the audit and their
individual responsibilities.
Patients who were yet to commence capecitabine therapy after 1
January 2008 were advised, as part of their pre-chemotherapy
discussion with medical or nursing staff, that fasting serum lipid
profiles would be required as part of their pre-chemotherapy
work-up.
Fasting serum lipid profiles were performed along with routine
pre-chemotherapy blood tests, at three pre-specified time points:
before commencement of capecitabine, midway through therapy at
cycle 3 or 4 and before the final cycle. Those with any abnormal
levels (42.1mmoll
 1) were to be followed up for 3 months after
the end of chemotherapy, or more often if required.
Any patient with a fasting serum TG result 45.0mmoll
 1
during the course of chemotherapy was referred to the first author
(COM) to ensure continuity and follow-up of future results. Data
relating to patient demographics, oncology history, past medical
history, concomitant medications, alcohol intake, renal function,
body surface area, baseline blood pressure and family history of
diabetes mellitus and hyperlipidaemia were collected. The patients,
their oncologists and GPs were informed of the result and the
recommendation for lipid-lowering therapy.
It was felt that the development of hypertriglyceridaemia should
not interrupt capecitabine anti-cancer therapy; rather, that it be
appropriately treated with oral fenofibrate (267mg once daily),
with close follow-up. In published case reports, patients did have
capecitabine therapy withheld or interrupted; however, following
discussion with our metabolic team, we did not feel that this was
warranted, particularly given the importance of the chemotherapy.
RESULTS
A total of 304 patients were treated with capecitabine
(84 capecitabine alone, 220 in combination with oxaliplatin) for
colorectal malignancies, with 1505 courses delivered during the
18-month observation period between 1 January 2008 and 30 June
2009. Figure 1 shows the flow of patients by means of a Consort
diagram, and the patient characteristics of those who developed
CIHT are summarised in Table 2.
A total of 212 patients (70%) were screened at baseline for
hypertriglyceridaemia as part of this study. Of these, 30 were
known to have pre-existing diabetes (14.1%). Unfortunately, only
36% of patients were screened at all three time points during
therapy as planned, because of patient refusal or non-compliance
with fasting, appointment scheduling difficulties making fasting
problematic or other failures in the system.
Six patients were found to have raised TGs before commencing
capecitabine and were referred directly to their GP to start
corrective treatment. None of those who had TG levels repeated
during chemotherapy (n¼3) had any significant rise in their TGs
with concomitant fibrate administration.
All eight patients who developed CIHT during the study period
were being treated with the combination regimen of capecitabine
and oxaliplatin. This was in contrast to the group of nine patients
noted to have developed CIHT during 2007, which led to the
development of the study. Of these, 66% had been receiving
Table 1 Management protocol for raised serum triglycerides
Abnormal level Action
Serum TG level 45mmoll
 1 pre
chemotherapy
K Refer directly to GP for investigation and/or management
Fasting serum TG level 5–10mmoll
 1
during chemotherapy
K Calculate CVD risk prediction using validated prediction charts (from Williams et al, 2004); if CVD risk 420%
over next 10 years, start fenofibrate as given below, if cancer-related prognosis is sufficient to justify this
(43 months)
Serum TG level 410mmoll
 1 during
chemotherapy
K Commence oral fenofibrate (267mg) daily (unless any contraindications)
K Inform patient and GP of result and advice
K Repeat serum TG level after 1–2 months to ensure normalisation of TG level
K Discontinue fenofibrate 3 months after end of chemotherapy if TG improves to o2.1mmoll
 1 and CVD risk
score is o20%
K Advise further repeat lipid profiling 3 months after discontinuation of fenofibrate
Grossly elevated TG level
(415mmoll
 1) at any time
K As per serum TG level 410mmoll
 1, but also refer directly to metabolic team for investigation
Abbreviations: CVD¼cardiovascular disease; GP¼general practitioner; TG¼triglycerides.
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scapecitabine monotherapy. However, by the time of commencement
of the study in 1 January 2008, the combination regimen had been
widely adopted in our unit to be the standard of care for colorectal
cancer, and indeed only 26% of the entire screened population in
the prospective study had received capecitabine alone.
In the group of eight patients with CIHT, only one had
previously been diagnosed with dyslipidaemia and was receiving
statin therapy. Two patients had previously had lipid screening,
which had been normal. No patients had a history of ischaemic
heart disease (given the side-effect profile of capecitabine) and one
had a history of treated hypertension. All patients had a normal
creatinine clearance and none were grossly overweight, but two
consumed more than the safe recommended limit of alcohol. The
median age was 54 years. Four had had previous separate lines of
capecitabine chemotherapy for their malignancy.
Six (3%) of the non-diabetic patients developed significantly
raised TGs and were commenced on fenofibrate as per protocol.
Two patients with non-insulin-dependent diabetes (6%) developed
hypertriglyceridaemia and there was also a definite trend towards
moderately raised TGs in the diabetic group; 14 (47%) were shown
to have TG levels above the upper limit of the normal range
(42.1mmoll
 1). The median fasting TG level for these diabetic
patients with moderately raised TG levels (between 2.1 and
5mmoll
 1) at any time point was 3.29mmoll
 1.
The patients with the highest TG levels were those with mild or
moderate derangement of their TG levels at baseline, before
commencement of capecitabine therapy. There was only one case
of NCI CTC grade 4 TGs (defined as 421mmoll
 1, 410 times the
ULN) in this audit period. This is in contrast to the multiple
grossly deranged levels observed anecdotally in the preceding year.
This may be a reflection of the prospective pre- and early-
treatment testing, and the implementation of a standard manage-
ment policy for raised TGs.
The TG levels of the eight patients with severely raised TG are
displayed graphically in Figure 2. Levels of serum glucose and total
cholesterol at the time of the highest serum TG level are also shown
for each patient. There was no evidence of hepatic steatosis in any
patients with CIHT.
Outcomes
Treatment with standard fenofibrate (267mg daily) was successful
with complete TG level normalisation in all but one case.
Normalisation was also sustained at 3 months of follow-up. In
one patient, the serum TG level doubled on discontinuation of
fenofibrate therapy and had to be restarted. Three patients
remained on fenofibrate therapy at their last clinic visit, but five
had discontinued therapy after 3 months with a normal serum TG
Table 2 Characteristics of patients with CIHT
Variable Patients with CIHT requiring treatment (n¼8)
Median age (years) 54 (range 44–69)
Site of primary tumour Colon: 5; rectum: 2; unknown: 1
Chemotherapy regimen Capecitabine/oxaliplatin combination: 8 patients
Capecitabine alone: 0 (total screened population receiving capecitabine alone: 56 (26%))
Treatment intent Adjuvant: 5
Palliative: 3
History of diabetes 2 Patients, both non-insulin-dependent (total number screened diabetic patients¼30)
Known history of dyslipidaemia or any lipid-
lowering therapy
Dyslipidaemia: 1 patient receiving atorvastatin therapy before chemotherapy, but no previous
fibrate therapy
Lipids never previously tested: 5
Lipids previously tested but normal: 2
Previous history of ischaemic heart disease None
Previous history of hypertension 1 Patient on anti-hypertensive therapy
Previous line of capecitabine therapy 4 Patients
Renal function All patients with documented creatinine clearance of 460mlmin
 1
Alcohol consumption Never consume: 3
Moderate consumption: 3
Above safe recommended limit: 2
Median body surface area (m
2) 1.84 (range 1.64–2.28)
Abbreviation: CIHT¼capecitabine-induced hypertriglyceridaemia.
Patients screened at
baseline, but not at all
planned time points to
constitute sufficient
follow-up
(n =102)
Patients receiving
capecitabine for
colorectal cancer
01/01/2008–30/06/2009
(n =312)
Excluded (n=8)
Did not receive more than one cycle
therapy
(n=8)
304 Patients
Excluded (n =92)
Baseline TG screen not
performed:
-Patient refusal
-Non-co-operation with
fasting
-Other system failure
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Case study analysis and
long-term follow-up of
abnormal TG results
(n =8)
Figure 1 Patient flow diagram.
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slevel, as per protocol. Some patients had frequent follow-up serum
TG sampling for up to 1 year, which was at their clinicians
discretion, and these remained normal.
One patient diagnosed with CIHT had a cerebral infarction after
cycle 2 of capecitabine/oxaliplatin. His TGs had risen significantly
since starting of treatment (16.6mmoll
 1 fasting from pre-
treatment non-fasting level of 10.25mmoll
 1). There were no
known cases of acute pancreatitis in the patients audited.
DISCUSSION
This is the first study to our knowledge that prospectively
evaluated changes in fasting serum TGs with capecitabine therapy
in standard oncology practice. The frequency of CIHT observed in
our population who were screened at any time was 3.7%, which
would be classed as a ‘common’ undesirable effect (41% and
o10%) rather than ‘uncommon’, as currently stated in the
Summary of Product Characteristics (Roche Pharmaceuticals,
2009). It is possible that this percentage would have been higher
had there not been a robust policy for early management of
hypertriglyceridaemia, including those detected at baseline. There
was a trend towards increased risk of CIHT in patients with
diabetes, but no other clear risk factors were identified, other than
those with mild-to-moderate TG derangement at baseline.
In 80% of the cases requiring lipid-lowering therapy, CIHT
responded well to fibrate treatment. There were no acute serious
clinical consequences of CIHT in our population, although our
early-treatment policy may have been a factor. In the case of the
patient with the ischaemic stroke while on capecitabine/oxaliplatin
chemotherapy, his pre-existing non-fasting hypertriglyceridaemia
may have increased the risk, but the additional impact of the
further rise in TG on capecitabine is unknown.
This was the first time that fasting lipid screening tests had been
incorporated into standard chemotherapy practice in our cancer
centre. All staff groups were informed about the new lipid
screening policy, and information routinely given to each new
patient starting treatment. Despite this, lipid testing was only
performed in 70% of patients and at all three time points in 36%.
This highlights the difficulties in performing non-standard tests
outside a formal clinical trial setting. A particular difficulty in
preventing patient dropout was the requirement to fast for
12hours; this can be disruptive to patients’ lifestyles and
complicate appointment scheduling, particularly for patients with
diabetes. Undoubtedly, however, there were practical benefits in
having a clear protocol to follow when raised TGs were identified,
as this is something oncologists do not normally treat.
We acknowledge that this study would undoubtedly be more
succinct if all patients were simply receiving capecitabine monotherapy,
rather than the majority also receiving oxaliplatin. However, this
reflected the change in our practice at the time to use combination
therapy, as standard, and it would clearly be unethical to withhold
oxaliplatin in the interests of such a project. In addition, it would take a
considerable amount of time to obtain sufficient numbers of patients
receiving capecitabine alone to obtain a meaningful conclusion.
Importantly, hypertriglyceridaemia, to our knowledge, has not
previously been reported with oxaliplatin alone and specifically not
with the FOLFOX (combination oxaliplatin with infusional 5-FU)
regimen, which has been commonly used worldwide since B2004.
Nevertheless, we cannot exclude an interaction between the two drugs.
The underlying mechanism leading to CIHT is currently unknown.
Hypertriglyceridaemia has not been reported as a side effect of 5-FU,
suggesting that the effect is related to the capecitabine itself or its
metabolites before the formation of 5-FU. Given its perceived rarity,
the underlying mechanism has not so far been studied in detail (Bar-
Sela and Haim, 2009), but one theory postulated is that capecitabine
may reduce the activity of lipoprotein lipase and hepatic TG lipase
(Stathopoulos et al, 2007; Garg et al, 2009).
As a result of our audit, we concluded that continuing routine
lipid screening of all our patients receiving capecitabine-contain-
ing chemotherapy regimens is not justified.
However, it is important that oncology teams are aware of this
potentially medically important side effect, and consideration
should be given to lipid monitoring in patients with established
diabetes or dyslipidaemia (Stathopoulos et al, 2007; Bar-Sela and
Haim, 2009; Garg et al, 2009). We would suggest serum lipid
sampling for those patients at baseline and after 2 or 3 cycles of
capecitabine, and recommend having an agreed policy for the
management of hypertriglyceridaemia when it is detected.
Importantly, and in contrast to previous published case reports,
our protocol did not involve discontinuation or interruption of
capecitabine chemotherapy due to CIHT and all patients in our
group were safely treated with immediate lipid-lowering therapy
(with the sole exception of the patient with cerebral infarction,
whose capecitabine was discontinued on that basis) and close
follow-up of their serum TG levels.
ACKNOWLEDGEMENTS
We thank the outpatient chemotherapy unit staff, Ian Macdonald,
for data retrieval, the GI multidisciplinary teams and, most
importantly, the patients.
REFERENCES
Bar-Sela G, Haim N (2009) Uncontrolled hypertriglyceridemia induced by
capecitabine: case report and review of the literature. Cancer Chemother
Pharmacol 63(5): 779–782
Budman DR, Meropol NJ, Reigner B, Creav e nP J ,L i c h t m a nS M ,B e r g h o r nE ,B e h r
J, Gordon RJ, Osterwalder B, Griffin T (1998) Preliminary studies of a novel
oral fluoropyrimidine carbamate: capecitabine. JC l i nO n c o l16(5): 1795–1802
Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R,
Koski S, Lichinitser M, Yang T-S, Rivera F, Couture F, Sirzen F,
Saltz L (2008) Randomized phase III study of capecitabine plus
oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as
first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):
2006–2012
0
5
10
15
20
25
30
35
Prechemo
Midpoint 1
Midpoint 2
End of cape
F/U
F/U 2
[Glc] at highest TG
Chol at highest TG
Serum testing time points
S
e
r
u
m
 
T
G
 
l
e
v
e
l
s
 
m
m
o
l
 
l
–
1
Pt 1
Pt 2
Pt 3
Pt 4
Pt 5
Pt 6
Pt 7
Pt 8
Upper limit
of normal for
serum [TG]:
2.1mmol/l
 
Figure 2 Triglyceride (TG) levels over time in eight patients with
capecitabine-induced hypertriglyceridaemia requiring lipid-lowering therapy.
The colour reproduction of this figure is available on the html full text
version of the manuscript.
Prospective study of capecitabine-induced hypertriglyceridaemia
CO Michie et al
620
British Journal of Cancer (2010) 103(5), 617–621 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sCassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B,
Van Oosterom AT (1998) A Phase I study of capecitabine in combination
with oral leucovorin in patients with intractable solid tumors. Clin
Cancer Res 4(11): 2755–2761
Garg R, Angus E, Fincher S (2009) Capecitabine-induced severe
hypertriglyceridaemia and diabetes: a case report and review of the
literature. Diabet Med 26(12): 1308–1309
Jones KL, Valero V (2003) Capecitabine-induced pancreatitis. Pharma-
cotherapy 23(8): 1076–1078
Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP (2006) Capecitabine-
induced hypertriglyceridemia: a report of two cases. Anticancer Res
26(3B): 2249–2251
Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N (2006) Capecitabine-
induced severe hypertriglyceridemia: report of two cases. Ann Pharmac-
other 40(2): 328–331
Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B,
Reigner B, Griffin T, Kaye S, Verweij J (1998) Phase I and pharmacologic
study of intermittent twice-daily oral therapy with capecitabine in patients
with advanced and/or metastatic cancer. JC l i nO n c o l16(9): 2977–2985
Orphanos GS, Stavrou NG, Picolos MK (2010) Hypertriglyceridemia: an
underdiagnosed side effect of Capecitabine chemotherapy. Acta Oncol
49(2): 262–263
Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ,
Osterwalder B, Verweij J, Twelves C (2000) A phase I and pharmaco-
kinetic study of the combination of capecitabine and docetaxel in
patients with advanced solid tumours. Br J Cancer 83(1): 22–29
Roche Pharmaceuticals (2009) Summary of Product Characteristics.
http://emc.medicines.org.uk/medicine/4619/SPC/Xeloda.
Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J,
Deliconstantinos G (2007) Capecitabine (Xeloda) as monotherapy in
advanced breast and colorectal cancer: effectiveness and side-effects.
Anticancer Res 27(3B): 1653–1656
Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G,
Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU,
Griffin T, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmaco-
kinetic study of the oral fluoropyrimidine capecitabine in combination
with paclitaxel in patients with advanced solid malignancies. J Clin Oncol
17(6): 1915–1925
Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS,
McG Thom S (2004) Guidelines for management of hypertension: report
of the fourth working party of the British Hypertension Society. JH u m
Hypertens 18: 139–185
Yucel H, van Warmerdam L (2010) Capecitabine-induced pancreatitis.
J Oncol Pharm Pract 16(2): 133–134
Prospective study of capecitabine-induced hypertriglyceridaemia
CO Michie et al
621
British Journal of Cancer (2010) 103(5), 617–621 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s